| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $38 to $50.
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...
Castle Biosciences' bullish structure is strengthening as momentum builds ahead of a possible breakout.
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $32 to $38.
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...